tbuckley/cabot-search huggingface dataset:
Preventing major bleeding in acute coronary syndromes: Lessons learned from the Global Registry of Acute Coronary Events (GRACE) Mauro Moscucci, Keith A. A. Fox, Christopher P. Cannon, Werner Klein, Kami White, Jos� L�pez-Send�n, Gilles Montalescot, Robert J. Goldberg, for the GRACE Investigators. University of Michigan Health System, Ann Arbor, MI, University of Massachusetts Medical School, Worcester, MA
Journal: Journal of the American College of Cardiology (2001)
Research Participation in Marginalized Communities — Overcoming Barriers
Authors: Katrina Armstrong, Christine Ritchie
Journal: New England Journal of Medicine (2022)

Interview with Dr. L. Ebony Boulware on the importance of racial and ethnic diversification and increased focus on equity in clinical and translational research. (13:19)Download Despite an increased focus on community engagement in research, barriers persist, including burdensome institutional and federal policies regarding payment for research participation and inadequate mechanisms to support longitudinal commitments to community partners.
Aids to Organotherapy.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Society Proceedings
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001
Authors: Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, Marina Maglakelidze, Iurie Bulat, Arunee Dechaphunkul, Wichit Arpornwirat, Chaiyut Charoentum, Chia-Jui Yen, Thomas Cheung Yau, Suebpong Tanasanvimon, Jedzada Maneechavakajorn, Aumkhae Sookprasert, Li-Yuan Bai, Wen-Chi Chou, Teerapat Ungtrakul, Mirjana Drinic, Joshua Tobias, Christoph C. Zielinski, Leslie Chong, Nicholas J. Ede, Mark T. Marino, Anthony J. Good
Journal: Clinical Cancer Research (2021)

Abstract Purpose: HER2/neu is overexpressed in up to 30% of gastroesophageal adenocarcinomas (GEA) and linked to poor prognosis. Recombinant mAbs to treat HER2/neu-overexpressing cancers are effective with limitations, including resistance and toxicity. Therefore, we developed a therapeutic B-cell epitope vaccine (IMU-131/HER-Vaxx) consisting of three fused B-cell epitopes from the HER2/neu extracellular domain coupled to CRM197 and adjuvanted with Montanide. This phase Ib study aimed to evaluate the optimal/safe dose leading to immunogenicity and clinical responses (https//clinicaltrials.gov/ct2/show/NCT02795988). Patients and Methods: A total of 14 patients with HER2/neu-overexpressing GEA were enrolled, and dose escalation (10, 30, 50 μg) was performed in three cohorts (C). Immunogenicity was evaluated by HER2-specific Abs and cellular responses, clinical responses by CT scans according to RECIST version 1.1. Results: IMU-131 was safe without vaccine-related significant local/systemic reactions or serious adverse events. A total of 11 of 14 patients were evaluable for changes in tumor size and vaccine-specific immune responses. One patient showed complete, 5 partial responses, and 4 stable diseases as their best response. HER2-specific IgG levels were dose dependent. In contrast to patients in C1 and C2, all patients in C3 mounted substantial HER2-specific Ab levels. In addition, cellular vaccine responses, such as Th1-biased cytokine ratios and reduced regulatory T cell numbers, were generated. Progression-free survival was prolonged in C3, correlating with the vaccine-specific humoral and cellular responses. Conclusions: IMU-131 was well tolerated and safe. The induced HER2-specific Abs and cellular responses were dose dependent and correlated with clinical responses. The highest dose (50 μg) was recommended for further evaluation in a phase II trial, with chemotherapy + IMU-131 or chemotherapy alone, which is currently ongoing.
Adjustment to visual loss
Authors: C. Margo
Journal: JAMA (1982)

MANY persons handicapped by poor vision do not use services that could be of benefit to them because information about available resources is difficult to obtain. Most of these services are provided by agencies and private organizations outside the medical community, and there is limited knowledge of them among physicians, ophthalmologists included.<sup>1</sup>Partially sighted persons can, however, be given the opportunity to obtain vital services if all physicians acquire this needed information and help disseminate it. Almost 11 million people in the United States suffer from varying degrees of decreased vision that cannot be restored to normal by corrective lenses or surgery. Persons with subnormal vision functionally fall into two categories: those with remaining usable vision (low vision) and those who are blind. The educational objectives for persons with low vision are markedly different than those for the totally blind. Persons with low vision require special education and training
Granulocyte-Macrophage Colony-Stimulating Factor Mitigates the Neutropenia of Combined Interferon Alfa and Zidovudine Treatment in Acquired Immune Deficiency Syndrome-Associated Kaposi's Sarcoma
Authors: David T. Scadden, Harriet A. Bering, James D. Levine, Jocelyn Bresnahan, Lydia Evans, Carol Epstein, Jerome E. Groopman
Journal: Journal of Clinical Oncology (1992)

Units of measure were incorrect in two reports: In "Granulocyte-Macrophage Colony-Stimulating Factor Mitigates the Neutropenia of Combined Interferon alfa and Zidovudine Treatment in Acquired Immune Deficiency Syndrome-Associated Kaposi's Sarcoma" by Scadden et al (J Clin Oncol 9:802–808, 1991), under "Treatment Regimen," the unit of measure for granulocyte-macrophage colony-stimulating factor should have been "µg/m 2 ." In the editorial, "Transfusion-Associated Graft-Versus-Host Disease" by K. Anderson (J Clin Oncol 9:1727–1730, 1991), the unit of measure for irradiation of blood products should have been "Gy."
BOOK REVIEWS
Authors: F. P. KUHAJDA
Journal: JNCI Journal of the National Cancer Institute (1990)

BOOK REVIEWS Interpretation of Breast Biopsies. Second Edition . Darry Carter ed. New York : Raven Press , 1990 , 246 pp. $65. FRANCIS P. KUHAJDA FRANCIS P. KUHAJDA Department of Pathology Johns Hopkins Hospital600 N. Wolfe St. Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 16, 15 August 1990, Pages 1356–1357, https://doi.org/10.1093/jnci/82.16.1356-a Published: 15 August 1990
In Brief
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The role of m6A RNA methylation in cancer metabolism
Authors: Yuanyuan An, Hua Duan
Journal: Molecular Cancer (2022)

Abstract Metabolic reprogramming is one of the main characteristics of malignant tumors, which is due to the flexible changes of cell metabolism that can meet the needs of cell growth and maintain the homeostasis of tissue environments. Cancer cells can obtain metabolic adaptation through a variety of endogenous and exogenous signaling pathways, which can not only promote the growth of malignant cancer cells, but also start the transformation process of cells to adapt to tumor microenvironment. Studies show that m6A RNA methylation is widely involved in the metabolic recombination of tumor cells. In eukaryotes, m6A methylation is the most abundant modification in mRNA, which is involved in almost all the RNA cycle stages, including regulation the transcription, maturation, translation, degradation and stability of mRNA. M6A RNA methylation can be involved in the regulation of physiological and pathological processes, including cancer. In this review, we discuss the role of m6A RNA methylation modification plays in tumor metabolism-related molecules and pathways, aiming to show the importance of targeting m6A in regulating tumor metabolism.
DIATHERMY IN CALCIFIED SUBDELTOID BURSITIS
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The association between preoperative CEA, the systemic inflammatory response and survival in colon cancer.
Authors: Allan Matthew Golder, James Hugh Park, David Mansouri, Paul G. Horgan, Donald C. McMillan, Campbell SD Roxburgh
Journal: Journal of Clinical Oncology (2022)

27 Background: Prior to curative surgery for colon cancer, carcinoembryonic antigen (CEA) has been reported to be a poor prognostic factor recommended for routine measurement, however the majority of studies evaluating this have not adjusted for the preoperative systemic inflammatory response (SIR) –widely shown to be associated with worse outcomes. The present study aims to analyse the association between preoperative CEA and long-term outcomes when adjusted for other factors including Systemic Inflammatory Grade (SIG). Methods: The effect on overall/cancer specific survival (OS/CSS) of preoperative CEA (&lt;5/5+) was examined in a regional cohort of patients undergoing surgery for colon cancer after adjustment for other clinicopathological factors including the SIR as measured by Systemic Inflammatory Grade (SIG). Results: 624 patients were identified undergoing curative surgery for colon cancer with a preoperative CEA available. For 3-year OS stratified by TNM Stage, CEA offered further prognostic value in patients with TNM Stage I (98% vs 75%, p=0.002), but not Stage II (p=0.444) or Stage III (p=0.351) disease. For 3-year OS stratified by SIG, CEA did not add further significant prognostic value for any SIG (all p&gt;0.05). On multivariate analysis, age (HR 1.65, p=0.020), sex (HR 0.53, p=0.001), mode of presentation (HR 1.93, p=0.008), TNM Stage (HR 1.83, p&lt;0.001) and SIG (HR 1.30, p&lt;0.001) remained significant for OS, but not CEA (p=0.620). Conclusions: The present results show that there is limited prognostic value of preoperative CEA. The SIR as measured by SIG should be routinely measured prior to curative colonic surgery. A mandatory reporting dataset is required in colorectal cancer and should include SIG. [Table: see text]
LRP10 in α-synucleinopathies
Authors: Christelle Tesson, Christine Brefel-Courbon, Jean-Christophe Corvol, Suzanne Lesage, Alexis Brice, Yves Agid, Mathieu Anheim, A.-M. Bonnet, Michel Borg, Christine Brefel-Courbon, Alexis Brice, Emmanuel Broussolle, Jean-Christophe Corvol, Philippe Damier, Alain Destée, Alexandra Dürr, Franck Durif, Suzanne Lesage, Ebba Lohmann, Maria Martinez, Pierre Pollak, Olivier Rascol, François Tison, Christine Tranchant, Marc Vérin, François Viallet, Marie Vidailhet
Journal: The Lancet Neurology (2018)
COVID-19 impact on diagnosis and staging of colorectal cancer: A single tertiary Canadian oncology center experience.
Authors: Mathias Castonguay, Corentin Richard, Marie-France Vachon, Rami Mohamad Nassabein, Danielle Charpentier, Mustapha Tehfe
Journal: Journal of Clinical Oncology (2022)

33 Background: COVID-19 pandemic urged public health to imposed drastic reduction on endoscopic activities and surgery, leading to delays that still not have been caught up today. The Ministry of Health and Social Services (MSSS) of Quebec conducted a study of the impact of those measures and reported a 66% reduction of colonoscopy and a 30% reduction of colorectal cancer (CRC) surgery activities during the first wave (March to May 2020). Whether those reduction had an impact on diagnosis and staging of CRC remains unknown. Methods: Demographic information of CRC diagnosed at Centre Hospitalier de l’Université de Montréal (CHUM) between January 1 2018 and March 12 2020 (pre-pandemic period), and March 13 2020 and June 30 2021 (pandemic period) were obtained from the SARDO registry and data regarding colonoscopy, surgery and staging at diagnosis (clinical or pathological as appropriate) were collected. Priority of elective colonoscopy was defined using the MSSS grading system ranging from P1 to P5. We compared delays to colonoscopy, delays to surgery and CRC staging of the pandemic period to the pre-pandemic period using one-way ANOVA, t tests and Chi-square tests as appropriate. Only delays in elective surgeries intended as first and curative treatment were analyzed. Results: 280 CRC diagnosis were made at the pre-pandemic period compared to 127 CRC diagnosis during the pandemic period. Mean diagnosis rates of the pandemic period tend to be lower (8.3 vs. 10.5 diagnosis/month, p=0.03) compared to the pre-pandemic period. 37.6% of patient in the pandemic period had a diagnosis of CRC during a hospitalization compared to 25.9% at the pre-pandemic period (p=0.048). 51.7% of elective colonoscopy leading to a diagnostic of CRC during the pandemic period did not meet required delays according to priority compared to 38.3% (p=0.049) during the pre-pandemic period. P3 colonoscopies (mostly indicated for a positive FIT and iron deficiency anemia) were the most affected (58.9 vs. 106.5 days, p˂0.001). P2 colonoscopy (indicated for suspected colorectal cancer) did not experienced an augmentation in delays (20.9 vs. 25.2 days, p=0.39). A mean of 3.5 elective curative surgeries per month were performed during the pandemic period compared to 3.4 at the pre-pandemic period (p=0.96), and mean delays for surgery were not affected (60.4 vs. 57 days, p=0.59). Stages at diagnosis did not differ (p=0.2). Most of the delayed colonoscopies led to a stage 0 or I CRC and did not lead to a higher stage at diagnosis (p=0.2). Conclusions: In our center, the COVID-19 pandemic led to overall less CRC diagnosis and increased diagnostic endoscopic delays without a higher rate of advanced stage disease. Delays for elective surgeries were quite similar once the CRC diagnostic established.
Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular ageing
Authors: Jaime Ibarrola, Seung Kyum Kim, Qing Lu, Jennifer J DuPont, Amanda Creech, Zhe Sun, Michael A Hill, Jacob D Jaffe, Iris Z Jaffe
Journal: Cardiovascular Research (2022)

Abstract Aims Vascular stiffness increases with age and independently predicts cardiovascular disease risk. Epigenetic changes, including histone modifications, accumulate with age but the global pattern has not been elucidated nor are the regulators known. Smooth muscle cell-mineralocorticoid receptor (SMC-MR) contributes to vascular stiffness in ageing mice. Thus, we investigated the regulatory role of SMC-MR in vascular epigenetics and stiffness. Methods and results Mass spectrometry-based proteomic profiling of all histone modifications completely distinguished 3 from 12-month-old mouse aortas. Histone-H3 lysine-27 (H3K27) methylation (me) significantly decreased in ageing vessels and this was attenuated in SMC-MR-KO littermates. Immunoblotting revealed less H3K27-specific methyltransferase EZH2 with age in MR-intact but not SMC-MR-KO vessels. These ageing changes were examined in primary human aortic (HA)SMC from adult vs. aged donors. MR, H3K27 acetylation (ac), and stiffness gene (connective tissue growth factor, integrin-α5) expression significantly increased, while H3K27me and EZH2 decreased, with age. MR inhibition reversed these ageing changes in HASMC and the decline in stiffness genes was prevented by EZH2 blockade. Atomic force microscopy revealed that MR antagonism decreased intrinsic stiffness and the probability of fibronectin adhesion of aged HASMC. Conversely, ageing induction in young HASMC with H2O2; increased MR, decreased EZH2, enriched H3K27ac and MR at stiffness gene promoters by chromatin immunoprecipitation, and increased stiffness gene expression. In 12-month-old mice, MR antagonism increased aortic EZH2 and H3K27 methylation, increased EZH2 recruitment and decreased H3K27ac at stiffness genes promoters, and prevented ageing-induced vascular stiffness and fibrosis. Finally, in human aortic tissue, age positively correlated with MR and stiffness gene expression and negatively correlated with H3K27me3 while MR and EZH2 are negatively correlated. Conclusion These data support a novel vascular ageing model with rising MR in human SMC suppressing EZH2 expression thereby decreasing H3K27me, promoting MR recruitment and H3K27ac at stiffness gene promoters to induce vascular stiffness and suggests new targets for ameliorating ageing-associated vascular disease.
THE TECHNIQUE OF OPERATIONS FOR CANCER OF THE BREAST.
Authors: CHARLES A. POWERS
Journal: JAMA (1895)

I do not feel that apology need be made for introducing to the society for discussion, the subject embodied in the foregoing title; the widespread and increasing prevalence of cancer of the breast,<sup>1</sup>its painful and terrifying features, and, above all, the very great attendant mortality, render it one of the most important of surgical conditions and one in which the most strenuous effort should be made to cure, and when cure be impossible, to ameliorate. The views which I have the honor of laying before you are based on some fifty operations in my own hospital and private practice. These operations have been done under modern methods and nearly all the cases have been followed from year to year. You will, therefore, pardon me if my observations are largely personal, and if I quote but little from other writers. With the causes of cancer in general, we are
Ophthalmology
Authors: Terrence P. O'Brien
Journal: JAMA (1994)

Since founding of the National Eye Institute in 1968, the expansion of vision research in the United States and throughout the world has vastly increased our knowledge of the eye and the visual process. Ophthalmologists also continue to make advances in understanding disease processes of the eye from front to back, contributing not only to prevention of blindness, but to improved quality of life and substantial savings in health-related costs. Disposable contact lenses were introduced commercially in the late 1980s and offered the promise of improved safety compared with nondisposable lenses for extended wear<sup>1</sup>: Epidemiologic studies completed prior to approval of disposable contact lenses documented a 10-fold increased risk of corneal ulcers associated with extended overnight wear of nondisposable contact lenses.<sup>2</sup>However, recent case-control studies<sup>3,4</sup>suggest that overnight wear of contact lenses, rather than whether the lenses are disposable or extended wear, is the overwhelming risk factor
Spinal cord stimulation for refractory angina pectoris patients: Data on clinical outcome from the prospective Italian registry F Di Pede, G Zuin, S Greco, D Rapati, M Roman�, G Neri, A Circo, A Capucci, G Lanza, P Stritoni, GM Actis Dato, E Marangoni, M Maritano, M Barbiero, G Dragagno. Cardiology Dept. Mestre-Venice, Italy
Journal: Journal of the American College of Cardiology (2001)